Top 3 Health Care Stocks That May Rocket Higher In September
CVS, Steris and Baxter are oversold healthcare stocks with RSI readings near or below 30, potentially offering undervalued buying opportunities.
Stocks · News reference
Steris Affirms FY2027 GAAP EPS Guidance of $9.00-$9.20 vs $9.08 Est
Steris (NYSE:STE) affirms FY2027 GAAP EPS guidance from $9.00-$9.20 to $9.00-$9.20 vs $9.08 analyst estimate..
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Steris (STE) Down 2.1% Since Last Earnings Report: Can It Rebound?
STERIS reported strong Q1 fiscal 2027 results with adjusted EPS of $2.59 (up 10.7% YoY) beating estimates by 1.97%, driven by higher volume, pricing, and productivity across all segments. However, revenues of $1.49 billion missed consensus by 0.83%. The company reaffirmed its fiscal 2027 guidance for 7-8% revenue growth and $11.10-$11.30 adjusted EPS. Despite solid earnings, shares have underperformed the S&P 500 by 2.1% since the report.
Recent Report Shows That Rep. Jared Moskowitz Sold Up to $30K Worth of Steris Stock
An official report on August 27, 2026 reveals Representative Jared Moskowitz's recent sale of Steris (NYSE:STE) stock, valued between $2,002 and $30,000. The transaction took place on July 13, 2026, as per the
UBS Maintains Buy on Steris, Lowers Price Target to $270
UBS analyst Patrick Wood maintains Steris (NYSE:STE) with a Buy and lowers the price target from $275 to $270.